In patients with amyotrophic lateral sclerosis (ALS), treatment with dextromethorphan/quinidine (DM/Q) was not shown to prevent failure of noninvasive respiratory management and had no effect on long-term deterioration of bulbar function, according to the results of a prospective, case-cohort study published in Respiratory Medicine. Investigators sought to evaluate whether treatment with...
Latest News
A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology. In a small, double-blinded clinical...
TARRYTOWN, N.Y. — Today, Diabetic Tussin, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves. This restock brings with it the Better Choices for Life mark from the American Diabetes Association® (ADA). This over-the-counter cold and cough...
Differentiation syndrome (DS), also termed retinoic acid syndrome or all-trans retinoic acid (ATRA) syndrome, is a recognized complication in patients undergoing treatment with newer targeted therapies for acute myeloid leukemia (AML), such as FLT3 and IDH inhibitors.¹ Evidence suggests the syndrome results from a severe systemic inflammatory response induced by...
HOUSTON, TX — Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced today it has completed enrollment for its Phase 1 trial of DOC1021, a unique dendritic cell vaccine, for Glioblastoma Multiforme (GBM). With the first patient enrolled in October 2021, DOC1021 has been administered to 16 patients across four...
HOUSTON, TX – The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Diakonos’ dendritic cell vaccine DOC1021 for malignant glioma. If the therapy is approved, the US-based immuno-oncology company is eligible for a potential seven years of market exclusivity in newly diagnosed or refractory glioblastoma multiforme,...
NEW YORK, NY and WALTHAM, Mass. – Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the initiation of the Phase 2 MaGic trial of DNTH103 in patients with generalized Myasthenia Gravis. The...
LEXINGTON, Mass. – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0 and 6.0 mg/kg) of its Phase 1 double-blind, placebo-controlled, randomized trial of belcesiran, an investigational GalXC™ RNAi therapeutic...
LEXINGTON, Mass. – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced the appointment of Rob Ciappenelli as Chief Strategy Officer, the promotion of Marc Abrams, Ph.D., to Senior Vice President, Discovery Research and the addition of Kristen Sheppard,...
LEXINGTON, Mass. – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced top-line results from its PHYOX4 study designed to evaluate the safety and tolerability of a single subcutaneous dose of nedosiran, Dicerna’s late-stage investigational GalXC™ RNAi therapeutic candidate in development for...